[Current and future prospects for anti-osteoporotic drugs].
Inoue
Daisuke
D
inoued@med.teikyo-u.ac.jp
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D002762:Cholecalciferol; D002986:Clinical Trials as Topic; D000069448:Denosumab; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D015195:Drug Design; D006801:Humans; D009942:Organometallic Compounds; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000008:administration & dosage; D010349:Patient Compliance; D053245:RANK Ligand; D020849:Raloxifene Hydrochloride; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D013876:Thiophenes
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D009942:Organometallic Compounds; D010281:Parathyroid Hormone; D053245:RANK Ligand; D020845:Selective Estrogen Receptor Modulators; D013876:Thiophenes; C081587:strontium ranelate; D002762:Cholecalciferol; D000069448:Denosumab; D020849:Raloxifene Hydrochloride